U.S. Pharmacovigilance Market to Reach USD 9.48 Billion by 2035, Growing at a CAGR of 10.45% from 2026–2035
Austin, Feb. 25, 2026 (GLOBE NEWSWIRE) — According to SNS Insider, The Pharmacovigilance Market size is estimated at USD 8.91 billion in 2025 and is expected to reach USD 24.69 billion by 2035, growing at a CAGR of 10.34% over 2026-2035.
Growing regulatory requirements for post-market surveillance, an increase in adverse drug reaction incidents, and the pharmaceutical industry’s expansion into emerging markets are driving the global pharmacovigilance market trend, which is a growing demand for drug safety monitoring solutions like adverse event reporting systems, signal detection platforms, and risk management services.
Pharmacovigilance Market Size and Forecast:
- Market Size in 2025: USD 8.91 billion
- Market Size by 2035: USD 24.69 billion
- CAGR: 10.34% from 2026 to 2035
- Base Year: 2025
- Forecast Period: 2026–2035
- Historical Data: 2022–2024
Request Instant Access to the Sample Report of Pharmacovigilance Market Forecast @ https://www.snsinsider.com/sample-request/3095
The U.S. Pharmacovigilance Market is projected to be USD 3.42 billion in 2025 and is expected to reach USD 9.48 billion in 2035, growing at a CAGR of 10.45% from 2026 to 2035.
Due to the stringent FDA rules, the extensive pharmaceutical R&D activities, and the well-established drug safety surveillance system, the United States is the largest market for pharmacovigilance. The market is growing as a result of government regulations, a high rate of adverse event reporting, and pharmaceutical companies’ increased investment in patient safety initiatives.
Stringent Regulatory Requirements and Compliance Mandates are Augmenting Market Expansion Globally
The implementation of FDA adverse event reporting systems, EMA pharmacovigilance guidelines, and WHO safety monitoring standards for increased drug safety surveillance and post-market monitoring have made strict regulatory requirements and compliance mandates the primary growth driver for the pharmacovigilance market share. The market’s foundation, the penetration of contract outsourcing and in-house markets, and the expansion of the market share globally are all being driven by these solutions for pharmaceutical safety management and risk mitigation.
High Implementation Costs and Resource Constraints May Hinder Market Expansion Globally
Since many small and medium-sized pharmaceutical companies struggle to set up comprehensive safety monitoring infrastructure and retain qualified pharmacovigilance professionals, the high implementation costs and resource constraints of pharmacovigilance systems also limit the growth of the pharmacovigilance market. For drug safety organizations, this could result in underreporting, a lack of system acceptance, and decreased efficiency. In areas where pharmaceutical businesses have limited funds and pharmacovigilance expertise is sparse, this leads to poor patient safety outcomes and stalled market growth.
Pharmacovigilance Market Segmentation Analysis:
By Product Life Cycle
Phase IV held the largest share of around 38.64% in 2025 due to the extensive post-market surveillance needs, long-term safety monitoring obligations, and exposure of a large patient population to commercialized drugs. The Phase III market is expected to register the fastest growth at a CAGR of nearly 11.12% during the forecast period of 2026-2035, due to the growing number of late-stage clinical trials and the need for stringent safety reporting.
By Service Provider
By 2025, the contract outsourcing segment contributed the largest revenue share of 61.23% due to cost-effectiveness, access to specialized expertise and scalability advantages for pharmaceutical companies. The in-house segment is projected to grow at the highest CAGR of about 10.87% between 2026 and 2035 due to the growing need for greater control over safety data and direct regulatory interaction capabilities.
By End-Use
The pharmaceuticals segment accounted for the largest share of the pharmacovigilance market with about 52.34%, owing to their extensive drug portfolios, global regulatory compliance obligations, and significant investment capacity for safety monitoring infrastructure. In addition, it is slated to grow at the fastest rate with a CAGR of around 10.56% throughout the forecast period of 2026–2035, as pharmaceutical companies seek comprehensive adverse event monitoring platforms, risk management system implementations, and patient safety enhancement capabilities.
For an In-Depth Strategic Briefing with Our Research Team, Connect Now @ https://www.snsinsider.com/request-analyst/3095
Pharmacovigilance Market Regional Insights:
Asia Pacific is the fastest-growing segment in the pharmacovigilance market with a CAGR of 12.18% in the forecasted period, as the awareness about drug safety monitoring, government regulatory harmonization initiatives, and pharmaceutical manufacturing expansion in developing nations is growing.
Due to a well-established pharmaceutical industry infrastructure, strict FDA safety reporting regulations, and heightened healthcare provider awareness of the significance of adverse event monitoring, North America held the largest revenue share of the pharmacovigilance market in 2025, which are more than 41.28%.
Major Players Analysis Listed in the Pharmacovigilance Market Report
- IQVIA Holdings Inc.
- Accenture plc
- Oracle Corporation
- PAREXEL International Corporation
- Cognizant Technology Solutions
- ArisGlobal LLC
- Syneos Health
- ICON plc
- Pharmaceutical Product Development (PPD)
- Laboratory Corporation of America (Labcorp Drug Development)
- Wipro Limited
- Capgemini SE
- Medpace Holdings, Inc.
- Freyr Solutions
- Veeva Systems Inc.
- Genpact Limited
- BioClinica (Clario)
- PRA Health Sciences
- Pfizer CentreOne
- Ergomed plc
- TAKE Solutions Limited
- Celegence (ITClinical)
- United BioSource Corporation (UBC)
- DrugSafety Services
- SIRO Clinpharm
Pharmacovigilance Market Recent Developments:
- In February 2025, it expanded its pharmacovigilance platform capabilities with AI-driven signal detection and automated case processing, aiming to improve drug safety monitoring efficiency and regulatory compliance across its global pharmaceutical client network.
- In May 2024, launched an enhanced cloud-native pharmacovigilance solution featuring real-time adverse event analytics and integrated regulatory reporting capabilities across global pharmaceutical markets, enhancing safety data management, compliance automation, and signal detection accuracy.
Purchase Single User PDF of Pharmacovigilance Market Intelligence Report @ https://www.snsinsider.com/checkout/3095
Exclusive Sections of the Report (The USPs):
- ADVERSE EVENT REPORTING METRICS – helps you understand global adverse event reporting volumes, case processing timelines, regulatory submission efficiency, and the distribution of serious versus non-serious safety events.
- TECHNOLOGY ADOPTION & AUTOMATION METRICS – helps you identify how AI, machine learning, cloud platforms, NLP-based case intake, and automated signal detection systems are transforming pharmacovigilance operations.
- REGULATORY COMPLIANCE & QUALITY METRICS – helps you evaluate compliance with global pharmacovigilance standards, safety reporting accuracy, inspection outcomes, and the effectiveness of risk management plans.
- OUTSOURCING & RESOURCE UTILIZATION METRICS – helps you analyze the role of contract research organizations, cost savings from outsourcing, workforce training trends, and the balance between in-house and outsourced safety case management.
- GLOBAL SAFETY MONITORING INSIGHTS – helps you assess how pharmaceutical companies strengthen drug safety monitoring, regulatory readiness, and operational efficiency across international markets.
Pharmacovigilance Market Report Scope:
| Report Attributes | Details |
| Market Size in 2025 | USD 8.91 Billion |
| Market Size by 2035 | USD 24.69 Billion |
| CAGR | CAGR of 10.34% From 2026 to 2035 |
| Base Year | 2025 |
| Forecast Period | 2026-2035 |
| Historical Data | 2022-2024 |
| Key Segments | • By product Life Cycle • By Service Provider • By Type • By Process Flow • By Therapeutic • By End Use |
| Regional Analysis/Coverage | North America (US, Canada), Europe (Germany, UK, France, Italy, Spain, Russia, Poland, Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Australia, ASEAN Countries, Rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Mexico, Colombia, Rest of Latin America). |
Rising Demand for Pharmacovigilance Market Data, Our Full Report Trend Analysis @ https://www.snsinsider.com/reports/pharmacovigilance-market-3095
About Us:
SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company’s aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.
CONTACT: Contact Data Contact Us: Rohan Jadhav - Principal Consultant Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK)
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. IndiaShorts takes no editorial responsibility for the same.
